|
Type of Company:
Type:
|
Company
|
Ownership: |
Privately Held |
Company Size: |
30 Employees In BC (30 Total)
30 In BC (30 Total)
|
Revenue: |
$1.90 Million CAD |
Year Founded: |
2001 |
Sector: |
Biotech/Life Sciences
Biotech/Life Sciences
|
Region: |
Lower Mainland / South Coast
Lower Mainland
|
Tags: |
IDR, Innate Defense Regulator, drug development, infectious disease, inflammatory disease
|
Profile Views: |
2,029 Company Profile Views |
|
|
Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), novel first in class drugs that selectively modulate the body's innate defenses without causing inflammation.
IDR products have major market potential for infectious disease, side effects of cancer therapies, and inflammatory disease. These products will significantly reduce morbidity and mortality in the rapidly growing population of "at-risk" immune suppressed and elderly patients. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization.
Synopsis
|
|
|
Date |
Type |
Amount |
Investors |
Date |
Type |
Amount |
Investors |
|
|
Share This Company Profile |
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|